News

Conference Coverage

Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options

01/16/2026

Krish Patel, MD

Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.

Krish Patel, MD, shared results...

01/16/2026

Oncology

Conference Coverage

Subcutaneous Mosunetuzumab Demonstrates Deep, Early Responses for Treatment-Naïve Follicular Lymphoma: Phase 2 MorningSun Trial

01/08/2026

John Burke, MD

John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.

John Burke, MD, reported that...

01/08/2026

Oncology

Conference Coverage

5-Year Data Show Durable Remissions With Tisagenlecleucel for R/R Follicular Lymphoma: ELARA Trial

01/08/2026

Stephen Schuster, MD

Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.

Stephen Schuster presented...

01/08/2026

Oncology

Conference Coverage

Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL

12/07/2025

Sairah Ahmed, MD

For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.

For patients with at least 3...

12/07/2025

Oncology

News

Real-World Safety Analysis Identifies Undocumented Adverse Events Among Patients With Follicular Lymphoma Treated With Obinutuzumab

12/03/2025

Emily Estrada

A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.

A real-world pharmacovigilance...

12/03/2025

Oncology

Videos

Emerging Targeted Therapies for Peripheral T-Cell Lymphoma

11/06/2025

Jia Ruan, MD, PhD

Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.

Jia Ruan, MD, shares insights...

11/06/2025

Oncology

News

CAR T-Cell Therapy Offers Superior Efficacy Over Bispecific Antibodies for R/R Follicular Lymphoma but With Higher Toxicity, Meta-Analysis Finds

11/05/2025

Emily Estrada

For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.

For patients with R/R FL,...

11/05/2025

Oncology

News

Fixed-Duration Epcoritamab Plus R2 Produces High Response Rates and Favorable Outcomes for R/R Follicular Lymphoma

11/05/2025

Emily Estrada

A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.

A regimen of fixed-duration...

11/05/2025

Oncology

News

CAR T-Cell Therapies Show Superior Survival Outcomes Compared to Real-World Salvage Treatments for R/R Follicular Lymphoma

11/05/2025

Emily Estrada

In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...

In a real-world setting, CAR...

11/05/2025

Oncology

Videos

Emerging Treatments for Patients With Relapsed/Refractory Follicular Lymphoma

10/16/2025

Erin Mulvey, MD

Erin Mulvey, MD, discusses novel treatment options for patients with relapsed/refractory follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Erin Mulvey, MD, discusses novel...

10/16/2025

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology